Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Fenofibrate’s Impact in Statin-Treated T2D Patients
JAMA Cardiol; ePub 2016 Dec 28; Elam, et al
Fenofibrate therapy appears to reduce cardiovascular disease in patients with diabetes with hypertriglyceridemia and low HDL cholesterol, according to a study involving more than 4,600 individuals.
Participants—all from the original ACCORD Lipid Trial and treated with statins—had type 2 diabetes with CVD or CVD risk factors and low HDL levels. Investigators followed them for a median of nearly 10 years, further analyzing CV outcomes in those previously treated with fenofibrate vs placebo. Among the results:
- No statistically significant difference was seen for fatal and nonfatal myocardial infarction and stroke, a finding that mirrored what was observed in the original ACCORD study.
- However, patients with dyslipidemia (triglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL) saw their odds of CVD reduced by 27%.
Elam M, Ginsberg H, Lovato L, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. [Published online ahead of print December 28, 2016]. JAMA Cardiol. doi:10.1001/jamacardio.2016.4828.